MX9706520A - Metodos para inhibir el cancer de ovario. - Google Patents
Metodos para inhibir el cancer de ovario.Info
- Publication number
- MX9706520A MX9706520A MX9706520A MX9706520A MX9706520A MX 9706520 A MX9706520 A MX 9706520A MX 9706520 A MX9706520 A MX 9706520A MX 9706520 A MX9706520 A MX 9706520A MX 9706520 A MX9706520 A MX 9706520A
- Authority
- MX
- Mexico
- Prior art keywords
- ovarian cancer
- methods
- inhibiting ovarian
- inhibiting
- hexamethyleneimido
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Se describe un método para inhibir al cáncer de ovario que comprende administrar a una humana en necesidad del mismo una cantidad efectiva de un compuesto que tiene la formula (I), en la que R1 y R3 son independientemente hidrogeno, -CH3, (a), o (b), en la que Ar es fenilo opcionalmente sustituido; R2 se selecciona del grupo que consiste de pirrolidina, hexametilenimido y piperidino; o una sal o solvato del mismo farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39595195A | 1995-02-28 | 1995-02-28 | |
US395951 | 1995-02-28 | ||
PCT/US1996/002621 WO1996026727A1 (en) | 1995-02-28 | 1996-02-27 | Methods of inhibiting ovarian cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9706520A true MX9706520A (es) | 1997-11-29 |
MXPA97006520A MXPA97006520A (es) | 1998-07-03 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
FI973521A (fi) | 1997-08-27 |
JPH11501033A (ja) | 1999-01-26 |
FI973521A0 (fi) | 1997-08-27 |
CA2214080A1 (en) | 1996-09-06 |
KR19980702553A (ko) | 1998-07-15 |
EP0729755A2 (en) | 1996-09-04 |
NO973963D0 (no) | 1997-08-28 |
EA199700200A1 (ru) | 1998-02-26 |
EP0729755A3 (es) | 1996-09-11 |
WO1996026727A1 (en) | 1996-09-06 |
ZA961564B (en) | 1997-08-27 |
IL117277A0 (en) | 1996-06-18 |
NO973963L (no) | 1997-08-28 |
HUP9801327A2 (hu) | 1999-06-28 |
CN1176600A (zh) | 1998-03-18 |
AU5028696A (en) | 1996-09-18 |
HUP9801327A3 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY132251A (en) | Methods of inhibiting cell-cell adhesion | |
AU7578794A (en) | Methods for inhibiting endometriosis | |
MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
UA27910C2 (uk) | Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с | |
MX9701334A (es) | Metodos para inhibir la degeneracion de protesis oseas. | |
MX9709466A (es) | Medicamento para inhibir el melanoma. | |
MX9701327A (es) | Metodos para inhibir el cancer endometrial. | |
MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
MX9702148A (es) | Metodos para inhibir la mitosis endometrial. | |
AU8155094A (en) | Methods of inhibiting hirsutism and alopecia in women | |
MX9706520A (es) | Metodos para inhibir el cancer de ovario. | |
MX9701359A (es) | Metodos para la inhibicion de la hiperplasia endometrial primaria. | |
MX9705940A (es) | Metodos y composiciones para inhibir los efectos de la interleucina 6. | |
MX9709536A (es) | Metodo para reducir el factor de transcripcion bef-1. | |
MX9705215A (es) | Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento. | |
MX9701331A (es) | Metodos para mantener los dientes y los huesos bucales. | |
MX9709651A (es) | Metodos para modulacion del factor de transcripcion nf-kb. | |
MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. | |
MX9705537A (es) | Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente. | |
MX9806036A (es) | Compuestos para inhibir tumores en el colon. | |
MX9705697A (es) | Metodos para reducir los niveles de calcio del suero. | |
MX9702853A (es) | Metodos para inhibir condiciones asociadas con el neuropeptido "y". |